AIC
OBIO icon

AWM Investment Company’s Orchestra BioMed OBIO Stock Holding History

AWM Investment Company’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-200,000
Closed -$2.56M – 115
2020
Q4 		$2.56M Hold
200,000
– – 0.33% 70
2020
Q3 		$2.2M Buy
+200,000
New +$2.25M 0.36% 67

Other funds holding OBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AC
Amitell Capital Singapore $62.4M AUM 75.98% 1-Year Est. Return

AWM Investment Company's OBIO Position: Q1 2021 in Review

AWM Investment Company sold out of Orchestra BioMed (OBIO) in Q1 2021, closing a stake of 200,000 shares — an estimated $2.56M sold.

AWM Investment Company first reported a position in OBIO in Q3 2020 and held it in 2 quarters. The position peaked at $2.56M in Q4 2020. 46 funds tracked by Wall St. Rank hold OBIO as of Q1 2021.

  • AWM Investment Company reported no remaining Orchestra BioMed position as of Q1 2021 after selling out during the quarter.
  • AWM Investment Company sold 200,000 Orchestra BioMed shares in Q1 2021, an estimated $2.56M.
  • AWM Investment Company first reported a position in Orchestra BioMed in Q3 2020 and held it in 2 quarters.
  • AWM Investment Company's Orchestra BioMed position peaked at $2.56M in Q4 2020.
  • 46 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2021.

Based on AWM Investment Company's 13F filing for Q1 2021, filed 13 May 2021.